Adbri Ltd DR (OTC:ADLDY) Stock, Quote.Headers.trade-ideas

Adbri

Adbri Ltd DR

JP Morgan analyst Kian Abouhossein maintains Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) with a Neutral and raises the price target from $108 to $124.

News

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Morgan Stanley, Raises Price Target to $124

JP Morgan analyst Anthony Elian maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Neutral and raises the price target from $22.5 to $23.5.

JP Morgan Maintains Neutral on First Horizon, Raises Price Target to $23.5

Evercore ISI Group analyst Amit Daryanani maintains F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) with a In-Line and raises the price target from $240 to $270.

FFIV

Evercore ISI Group Maintains In-Line on F5, Raises Price Target to $270

Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) shares are trading lower after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43052123/fastenal-company-reports-2024-annual-and-fourth-quarter-earnings" rel="noreferrer noopener">reported fourth-quarter&nbsp;results</a>.
Fastenal reported sales growth of&nbsp;3.7%&nbsp;year-over-year to&nbsp;$1.825 billion, missing the consensus of&nbsp;$1.844 billion.
There was one more selling day in the&nbsp;fourth quarter&nbsp;of 2024 relative to the prior year period, and considering this, the company&#8217;s net daily sales increased&nbsp;by 2.1%. Growth remained slow due to a persistently weak manufacturing environment, further impacted by sharp year-end production cuts from major customers.
Foreign exchange fluctuations reduced sales by 20 bps in the quarter. Unit sales increased in the quarter due to growth at Onsite locations opened in the last two years along with larger customers not serviced through an Onsite. 
Weighted FASTBin/FASTVend signings (MEUs) rose&nbsp;24.3%&nbsp;Y/Y to 6,790; Weighted FASTBin/FASTVend installations rose&nbsp;12.2%&nbsp;Y/Y.
In the&nbsp;fourth quarter, FAST&#8217;s Digital Footprint represented&nbsp;62.2%&nbsp;of sales, an increase from&nbsp;58.1%&nbsp;a year ago.
The gross margin contracted to&nbsp;44.8%&nbsp;from&nbsp;45.5% a year ago quarter, primarily due to unfavorable customer and product mix, pressured fastener and safety product margins and higher import duty fees.
Operating income was&nbsp;$344.8 million&nbsp;(-2.6%&nbsp;Y/Y), and the margin was&nbsp;18.9%, a decline from&nbsp;20.1%&nbsp;in the same quarter of 2023.
The company&#8217;s&nbsp;fourth-quarter&nbsp;EPS was&nbsp;46 cents,&nbsp;missing <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the estimate of&nbsp;48 cents</a>.
Fastenal&#8217;s operating cash flow for the year was&nbsp;$1.173 billion, a decrease of&nbsp;18.1%&nbsp;year over year. The company held cash and equivalents of&nbsp;$255.8 million&nbsp;as of December end. The company did not repurchase any common stock in 2024 or 2023.
Total debt decreased to&nbsp;$200&nbsp;million&nbsp;(5.2%&nbsp;of total capital) at the end of the quarter. This compares to&nbsp;7.2%&nbsp;of total capital at the end of 2023.
The company signed 56&nbsp;new Onsite locations in the&nbsp;fourth quarter, resulting in 358 signings in 2024. Active Onsite locations rose&nbsp;11.5%&nbsp;to 2,031.
Outlook: For 2025, the company targets weighted FASTBin and FASTVend device signings <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">between 28,000 and 30,000 MEUs</a>.
The company expects 66% &#8211; 68% of the sales volume to account for the Digital Footprint during 2025.
In 2025, net investment in property and equipment is expected to be within the $265.0 million &#8211; $285.0 million range, up from $214.1 million in 2024.
Price Action: FAST shares are down 1.7% at $73.50 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43051358/us-stock-futures-inch-up-as-sp-500-is-poised-for-a-weekly-gain-despite-snapping-three-day-streak-all-11-sectors-to-report-growing-profits-in-2025-says-analyst" target="_blank" rel="noreferrer noopener">US Stock Likely To Open Higher Ahead of Trump&#8217;s Inaugration: All 11 Sectors To Report Growing Profits In 2025, Says Analyst</a></li>
</ul>
Photo via Shutterstock.

Earnings

Equities

Large Cap

Guidance

FAST

Fastenal Q4: Earnings Miss, 3.7% Sales Growth, Manufacturing Woes And More

Cantor Fitzgerald analyst C J Muse reiterates Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Overweight and maintains $95 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Western Digital, Maintains $95 Price Target

Evercore ISI Group analyst Glenn Schorr maintains Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) with a Outperform and lowers the price target from $53 to $51.

Evercore ISI Group Maintains Outperform on Bank of America, Lowers Price Target to $51

The C$1.67 per share offer by Agnico Eagle for O3 Mining appears to value O3 Mining at an Enterprise Value of C$162.8m1, representing a significant discount to both sell side analyst Net Present Value "NPV" estimates at C$1.6bn2, and in our analysis – updating pre-feasibility estimates – also a C$1.6bn NPV3.
In our assessment Agnico Eagle will maximize its profit participation in O3 Mining only by raising the price of its takeover offer, given what appears to be a significant gap between the current takeover offer and NPV, and assuming an otherwise constrained tender ratio by independent shareholders who would then retain as minority shareholders a significantly larger share of the development profit available.
In the scenario of the current offer price remaining unchanged, and assuming the 90% delisting threshold is not achieved, non-tendering shareholders may judge their optimal outcome as continued public float ownership alongside Agnico Eagle as majority owner and as a well-funded, and arguably best-in-class, development partner.
 LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- &nbsp;
GreenAsh Partners oversees investment funds including the GA-Courtenay Special Situations Fund, which holds 3,393,500 shares in O3 Mining, or 2.7% of the shares outstanding4.
On December 12th, 2024, Agnico Eagle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) announced a recommended takeover of O3 Mining (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/OIII#TSXV">OIII</a>) at an all cash offer for C$1.67 per share, which it has not yet declared as final5.
We believe independent shareholders will welcome the aspect of the deal design that requires just 662/3% acceptance by shareholders, and a condition which the offeror has reserved the right to waive to no less than 50% acceptance6. The attraction of this characteristic is in its prospective allowing of non-tendering shareholders a long-term profit participation in that listed O3 Mining equity remaining post-takeover and with Agnico Eagle as majority shareholder (assuming the 90% of tenders required for de-listing7 is not achieved).
However, we are perplexed at what appears to be the deeply discounted valuation&nbsp;of the proposed takeover of O3 Mining and a pricing level which may deliver no material advantage to Agnico Eagle, to the extent that, if shareholders agree with our assessment of deep undervaluation, this&nbsp;is likely to disincentivise meaningful tenders beyond the 39% irrevocables already committed8.
For an independent assessment of the Net Present Value of O3 Mining we would point to, prior to the takeover announcement, the published NPV estimates by a number of sell side brokers. For example, research by Canaccord, published on November 19th 2024, estimated the NPV of O3 Mining at C$1.6bn9.
By comparison, the C$1.67 per share offer by Agnico Eagle values the equity of O3 Mining at C$204m, yet this equates to an Enterprise Value "EV" of just C$162.8m post adjustments for net cash and investments including marketable securities10.
Even the 2022 pre-feasibility study ("PFS") of O3 Mining, written by Ausenco Engineering Canada and who can also be considered as independent experts, estimated a C$639m NPV (5% discount rate) for core asset the Marban Mining Project albeit using a $1,900 gold price input11, significantly below the current gold price of $2,700.
Simply by extrapolating the sensitivity scale in the same PFS, and applying cost base inflation estimates, in our analysis the NPV output today also rises to C$1.6bn, a match of the Canaccord estimate, and indicating the offer EV on an up-to-date basis may be at as much as a 90% discount to NPV.
A deeply discounted offer consideration is only rational from the perspective of an offeror when the additional cost of raising the offer sufficient to achieve 100% of tenders would exceed the profit otherwise sacrificed by the offeror due to the failure of its deeply discounted offer to achieve the full tender ratio (this profit sacrifice calculated as: the development profit [i.e. the gap between takeover price and NPV] multiplied by the percentage of shareholders that do not tender).
In this case, the gap between takeover price and NPV appears very significant, and as such, the optimal economic outcome from the perspective of Agnico Eagle may only be reached by a meaningful raise in their offer price, assuming for the alternative of an unchanged offer price that tenders are not materially higher than the minimum thresholds.
Naturally, we believe independent shareholders would welcome further public disclosure by either Agnico Eagle or the O3 Mining directors that would justify meaningful tenders if the current offer price is unchanged.
However, in the scenario that Agnico Eagle does not raise the offer price, whilst the minimum acceptance thresholds may be met given the 39% irrevocables already committed, it is unlikely in our view that the 90% threshold required for de-listing will be reached. We make this assessment in the context that we believe at the current pricing of the takeover it will instead be rational for a meaningful proportion of independent shareholders in O3 Mining to elect for continuing long-term participation in the deeply discounted public equity float of O3 Mining. This equity is also now prospectively significantly enhanced by its combination with a well-funded, and arguably best-in-class, development partner.

TSXV:OIII

Agnico Eagle Offers C$1.67 Per Share For O3 Mining, Valuing It At C$162.8M; GreenAsh Holds 2.7% Shares; Offer Requires 66.67% Shareholder Acceptance But Can Be Lowered To 50%; 90% Delisting Threshold Not Met

CRKN

Crown Electokinetics Partners With Electro Scan To Deploy Lead Pipe Detection Technology

In the current market session, Becton Dickinson Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) stock price is at $236.00, after a 0.13% decrease. However, over the past month, the company's stock went up by 3.87%, and in the past year, by 0.26%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1737124210_0.png" alt="Past Year Chart" />

<h3>Becton Dickinson P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 69.75 in the Health Care Equipment &amp; Supplies industry, Becton Dickinson Inc. has a lower P/E ratio of 40.32. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1737124210_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: Becton Dickinson

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 15 years by 2.05% on an annualized basis producing an average annual return of 13.94%. Currently, Stryker has a market capitalization of $146.39 billion. 
Buying $100 In SYK: If an investor had bought $100 of SYK stock 15 years ago, it would be worth $713.29 today based on a price of $384.00 for SYK at the time of writing.
<h3>Stryker's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737124209_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Evercore ISI Group analyst Amit Daryanani maintains Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) with a Outperform and raises the price target from $110 to $130.

ANET

Evercore ISI Group Maintains Outperform on Arista Networks, Raises Price Target to $130

Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>)(TSX:<a class="ticker" href="https://www.benzinga.com/stock/BHC#TSX">BHC</a>) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN&#xAE; (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program.
We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN&#xAE; delivers for the healthcare system in addition to sharing recommendations from The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) who gave XIFAXAN&#xAE; the highest possible recommendation (Grade I, A,1) via their practice guidelines. We will continue to be driven by our commitment to patients in advocating for a healthcare environment that supports patient access to critical medications as well as encouraging future innovation.

Biotech

General

TSX:BHC

Bausch Health And Salix Pharmaceuticals Announced That CMS Selected XIFAXAN 550 mg For Drug Price Negotiation Under Inflation Reduction Act, Effective 2027; XIFAXAN Approved For HE And IBS-D In Adults, Rated Grade I, A,1 By Liver Disease Associations

Sify Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) just disclosed its Q3 earnings on Friday, January 17, 2025 at 07:34 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Sify Technologies missed estimated earnings by -0.6%, reporting an EPS of $-0.6 versus an estimate of $0.0.
Revenue was up $20.20 million from the same period last year.
<h3>Past Earnings Performance</h3>
The company beat on EPS by $0.02 in the previous quarter, leading to a 3.0% drop share price change the next day.
Here's a look at Sify Technologies's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.019</td>
<td>-0.06</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>152.70M</td>
<td>148.20M</td>
<td>149.30M</td>
<td>139.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>122.67M</td>
<td>112.95M</td>
<td>116.05M</td>
<td>104.01M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Sify Technologies <a href="https://www.benzinga.com/quote/SIFY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SIFY

Sify Technologies Earnings Report: Q3 Overview

Guggenheim analyst Vamil Divan reiterates Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) from Neutral to Neutral.

KROS

Guggenheim Reiterates Neutral on Keros Therapeuticsto Neutral

WIIM

Novo Nordisk shares are trading lower after Ozempic and Wegovy were included in a list of 15 medications for Medicare drug price negotiations.

On Friday,&nbsp;Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released headline results from the STEP UP Phase 3b trial in the global STEP program.
Semaglutide 2.4 mg is <a target="_blank" href="https://www.globenewswire.com/news-release/2025/01/17/3011376/0/en/Novo-Nordisk-A-S-Semaglutide-7-2-mg-s-c-achieved-20-7-weight-loss-in-the-STEP-UP-obesity-trial-and-18-7-regardless-of-treatment-adherence.html" rel="noreferrer noopener">marketed under the brand</a> name Wegovy. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">Novo Nordisk&#8217;s Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges</a>
The trial included 1,407 randomized adults with obesity. All treatment arms were in conjunction with lifestyle intervention.
The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo.
When evaluating the effects of treatment if all people adhered to treatment&nbsp;from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo.
In addition, 33.2% of those who received semaglutide 7.2 mg achieved a weight loss of 25% or more after 72 weeks, compared to 16.7% with semaglutide 2.4 mg and 0.0% with placebo.
When applying the treatment policy estimand, people treated with semaglutide 7.2 mg achieved a superior weight loss of 18.7% compared to a reduction of 15.6% with semaglutide 2.4 mg and 3.9% with placebo.
In the trial, semaglutide 7.2 mg appeared to have a safe and well-tolerated profile.
The results from the second semaglutide 7.2 mg phase 3 trial, STEP UP T2D, in adults with type 2 diabetes and obesity are expected within the next few months.
Detailed results from the STEP UP trial are expected to be presented at a scientific conference in 2025.
Price Action: NVO stock is down 4.37% at $79.44 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/43053632/fda-approves-expanded-use-of-eli-lillys-ulcerative-colitis-drug-for-crohns-disease" target="_blank" rel="noreferrer noopener">FDA Approves Expanded Use Of Eli Lilly&#8217;s Ulcerative Colitis Drug For Crohn&#8217;s Disease</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Health Care

Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss

The crowd is scared, but smart money might be seeing an opportunity. The latest AAII Sentiment Survey just flashed a contrarian Buy signal, with bullish sentiment hitting its lowest level since <a href="https://www.benzinga.com/quote/SPY/news">the S&amp;P 500</a>&#8216;s November 2023 bottom. 
Historically, extreme pessimism has been a strong indicator of future gains, and for SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) investors, this could be the moment to lean in.
<h2 class="wp-block-heading">The Bearish Mood That Bulls Love</h2>
The American Association of Individual Investors (AAII) <a href="https://www.aaii.com/latest/article/249507-aaii-sentiment-survey-optimism-drops">survey</a> shows that only 25.4% of investors are bullish—far below the historical average of 37.5%. Meanwhile, bearish sentiment has jumped to 40.6%, its highest in a year. When the crowd is this fearful, market bottoms tend to form, making this a classic contrarian buy setup.
For SPY investors, the implications are clear: history suggests these extreme readings often mark a turning point. But technicals are sending mixed signals, creating a dilemma for those trying to time the next move.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/01/43051358/us-stock-likely-to-open-higher-ahead-of-trumps-inaugration-all-11-sectors-to-report-growing-profits-in-2025-says-analyst">US Stocks Likely To Open Higher Ahead of Trump&#8217;s Inaugration: All 11 Sectors To Report Growing Profits In 2025, Says Analyst</a>
<h2 class="wp-block-heading">SPY's Technical Setup: A Balancing Act</h2>
SPY has been on a tear over the past year, up 25.3%, but recent action suggests hesitation. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17083328/Screenshot-2025-01-17-at-6.19.48-PM.png" alt="" class="wp-image-738983" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17083328/Screenshot-2025-01-17-at-6.19.48-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17083328/Screenshot-2025-01-17-at-6.19.48-PM-300x232.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011725&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Trading at around $591.64, it&#8217;s sitting above key moving averages, reinforcing a bullish trend. However, signs of selling pressure are emerging:
<ul>
<li>Short-term strength: The eight-day and 20-day moving averages signal a bullish trend, supporting further upside.</li>
<li>Longer-term caution: SPY is trading below its 50-day moving average of $595.08, hinting at potential weakness.</li>
<li>MACD (moving average convergence/divergence) says "proceed with caution": With a negative 1.95 reading, momentum indicators suggest a possible slowdown.</li>
<li>RSI (relative strength index) at 50.11: Neither overbought nor oversold, meaning SPY is at an inflection point.</li>
</ul>
<h2 class="wp-block-heading">Investor Takeaway: Buy The Fear Or Sit Tight?</h2>
The AAII survey&#8217;s pessimistic reading suggests that fear is peaking, a historically bullish sign. But with SPY hovering near record highs and technicals flashing mixed signals, investors may need to balance optimism with caution. 
For contrarians, this could be a prime entry point. For others, waiting for a clearer technical setup might be the smarter move.
Read Next: 
<ul>
<li><a href="https://benzinga.com/analyst-ratings/analyst-color/25/01/43049404/bull-markets-last-for-79-years-on-average-but-third-year-returns-can-be-weak-says-this-research-firm">Bull Markets Last For 7.9 Years On Average But Third-Year Returns Can Be Weak, Says This Research Firm</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Broad U.S. Equity ETFs

Technicals

Signals

ETFs

Widespread Investor Pessimism Could Signal S&P 500 Upside

Guggenheim analyst Subbu Nambi reiterates Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Buy to Buy.

BRKR

Guggenheim Reiterates Buy on Brukerto Buy

Barrington Research analyst Alexander Paris maintains Universal Technical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) with a Outperform and raises the price target from $25 to $30.

Barrington Research Maintains Outperform on Universal Technical, Raises Price Target to $30

Guggenheim analyst John Difucci reiterates Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) with a Buy and maintains $83 price target.

Comments

Adbri Ltd DR

Adbri Ltd DR (ADLDY) Forecast

Adbri Ltd DR (OTC:ADLDY) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga